Isoniazid
-
Subject Areas on Research
- A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
- Antepartum or postpartum isoniazid treatment of latent tuberculosis infection.
- Central nervous system infection and cutaneous lymphadenitis due to Mycobacterium kansasii in an immunocompetent patient.
- Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™.
- Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats.
- Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
- Detection of hydrazine, methylhydrazine and isoniazid by capillary electrophoresis with a 4-pyridyl hydroquinone self-assembled microdisk platinum electrode.
- Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial.
- Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial.
- Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
- Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries.
- Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
- Isoniazid preventive therapy in medium-incidence settings: the price is right.
- Letter: Treatment of meningitis and encephalitis.
- Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis.
- Metabolic effects of isonicotinic acid hydrazid (INH) toxicity in Saccharomyces cerevislae.
- Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
- Monitored isoniazid prophylaxis for low-risk tuberculin reactors.
- One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.
- Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
- Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture.
- Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection.
- Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
- Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania.
- Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.
- Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
- Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
- The action of oxygen and oxygen at high pressure on inhibitory transmission.
- Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
- Three months of rifapentine and isoniazid for latent tuberculosis infection.
- Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
- [Editorial: New problems in the diagnosis and classification of silicosis and its prevention].